Delivery Order SPE2DR25D9227-SPE2DR26FFLP2
- Not listed
- The Defense Logistics Agency (DLA) issued a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/mL, a biologic pharmaceutical product. Awarded on January 8, 2026, this firm fixed-price delivery order is issued without set-aside designation and reflects DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The place of performance is Park Ridge, Illinois, with an ultimate completion date of January 9, 2026. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for FASENRA Pen 30 MG/ML. The award, issued on January 9, 2026, with an ultimate completion date of January 12, 2026, utilizes firm fixed-price pricing with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense...
- The Defense Logistics Agency issued a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/ml on January 8, 2026, with an ultimate completion date of January 9, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded this firm fixed-price delivery order without a set-aside designation. The award represents one of numerous delivery orders issued under DMS Pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $4,887.00, is for the supply of FASENRA PEN 30 MG/MLML, a pharmaceutical product. This delivery order is under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group that has a ceiling value of up to $499,999,999 and runs through December 31, 2025. The IDC allows DLA to...
- The Defense Logistics Agency issued a delivery order valued at $14,962.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA PEN 30 MG/ML. This firm fixed-price delivery order, awarded on January 5, 2026, with an ultimate completion date of January 6, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award...
- The Defense Logistics Agency awarded a $19,950 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for FASENRA PEN 30 MG/ML. The award, issued on January 7, 2026, with an ultimate completion date of January 8, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group is performing work at its Park Ridge facility and...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,550.00 by the Defense Logistics Agency (DLA) on September 12, 2025. The delivery order, which is scheduled for completion by October 3, 2025, covers the supply of FASENRA Pen 30 mg/mL, a prescription pharmaceutical product, with performance to take place in Conshohocken, Pennsylvania. This award was made without a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The contract is a firm fixed-price delivery order with an ultimate completion date of January 7, 2026, and was issued without a set-aside designation. DMS Pharmaceutical Group is performing work at its headquarters location in Park Ridge, Illinois. This...
- The Defense Logistics Agency awarded a delivery order valued at $7,481.25 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA (benralizumab) pen 30 mg/mL. This firm fixed-price delivery order, issued on January 7, 2026, with an ultimate completion date of January 8, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award...
- The Defense Logistics Agency awarded a $9,975 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for FASENRA (benralizumab) 30 mg/mL pen injectors. The award was issued on January 9, 2026, with an ultimate completion date of January 12, 2026, and no set-aside designation was applied. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract...
- SPE2DR25D9227Indefinite Delivery Contract
- SPE2DR25D9227-SPE2DR26FFLP2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,481.25 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/ml on January 9, 2026, with completion targeted for January 12, 2026. This firm fixed-price delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, that specializes in distributing branded and generic prescription medications, biologics, vaccines, and medical consumables to federal agencies, particularly the Department of Defense. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA, designated SPE2DR and awarded under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative on November 13, 2025. The parent IDC carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods. The PPV-G GEN V program is a $30.3 billion government-wide acquisition strategy through which DLA establishes multiple regional prime vendor contractors to supply pharmaceutical products supporting Department of Defense healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.5k | 1/8/26 |